{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:10:25Z","timestamp":1773411025626,"version":"3.50.1"},"reference-count":33,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2014]]},"DOI":"10.1248\/bpb.b14-00254","type":"journal-article","created":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T23:26:03Z","timestamp":1406849163000},"page":"1330-1335","source":"Crossref","is-referenced-by-count":16,"title":["Distinct Interaction of Nilotinib and Imatinib with P-Glycoprotein in Intracellular Accumulation and Cytotoxicity in CML Cell Line K562 Cells"],"prefix":"10.1248","volume":"37","author":[{"given":"Yuji","family":"Yamakawa","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University"},{"name":"Department of Pharmacy, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[{"name":"Division of Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center"},{"name":"Department of Clinical Pharmacology, Group for Translational Research Support Core, National Cancer Center Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misato","family":"Yuki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Infectious Diseases, Kumamoto University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University"},{"name":"Department of Pharmacy, Kumamoto University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med.<\/i>, 354, 2542\u20132551 (2006)."},{"key":"2","unstructured":"2) Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R. U KM, Staten AM, Pazdur R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res.<\/i>, 8, 935\u2013942 (2002)."},{"key":"3","unstructured":"3) Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett.<\/i>, 249, 121\u2013132 (2007)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood<\/i>, 108, 1328\u20131333 (2006).","DOI":"10.1182\/blood-2005-12-010132"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell<\/i>, 7, 129\u2013141 (2005).","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"6","unstructured":"6) Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators. Nilotinib versus<\/i> imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med.<\/i>, 362, 2251\u20132259 (2010)."},{"key":"7","unstructured":"7) Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH. Drug transporters and imatinib treatment: implications for clinical practice. Clin. Cancer Res.<\/i>, 17, 406\u2013415 (2011)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood<\/i>, 104, 3739\u20133745 (2004).","DOI":"10.1182\/blood-2003-12-4276"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro<\/i> sensitivity to imatinib. Blood<\/i>, 108, 697\u2013704 (2006).","DOI":"10.1182\/blood-2005-11-4687"},{"key":"10","unstructured":"10) Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin. Pharmacol. Ther.<\/i>, 83, 258\u2013264 (2008)."},{"key":"11","unstructured":"11) Yamakawa Y, Hamada A, Shuto T, Yuki M, Uchida T, Kai H, Kawaguchi T, Saito H. Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. Clin. Pharmacol. Ther.<\/i>, 90, 157\u2013163 (2011)."},{"key":"12","unstructured":"12) Hamada A, Miyano H, Watanabe H, Saito H. Interaction of imatinib mesilate with human P-glycoprotein. J. Pharmacol. Exp. Ther.<\/i>, 307, 824\u2013828 (2003)."},{"key":"13","unstructured":"13) Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A, Nakayama H, Kawaguchi T, Saito H. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm. Res.<\/i>, 25, 827\u2013835 (2008)."},{"key":"14","unstructured":"14) Vasconcelos FC, Silva KL, Souza PS, Silva LF, Moellmann-Coelho A, Klumb CE, Maia RC. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin. Cytom.<\/i>, 80, 158\u2013166 (2011)."},{"key":"15","unstructured":"15) Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during imatinib treatment. Cancer Genet. Cytogenet.<\/i>, 162, 57\u201362 (2005)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Jorgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia<\/i>, 23, 1999\u20132006 (2009).","DOI":"10.1038\/leu.2009.166"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, Boudriot U, Neubauer A. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia<\/i>, 21, 1267\u20131275 (2007).","DOI":"10.1038\/sj.leu.2404638"},{"key":"18","unstructured":"18) Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM. Evidence that resistance to nilotinib may be due to BCR-ABL, P-gp, or Src kinase overexpression. Cancer Res.<\/i>, 68, 9809\u20139816 (2008)."},{"key":"19","unstructured":"19) Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, Orr MS, Sridhara R, Booth B, Leighton JK, Timmer W, Harapanhalli R, Dagher R, Justice R, Pazdur R. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin. Cancer Res.<\/i>, 14, 5325\u20135331 (2008)."},{"key":"20","unstructured":"20) Yuki M, Yamakawa Y, Uchida T, Nambu T, Kawaguchi T, Hamada A, Saito H. High-performance liquid chromatographic assay for the determination of nilotinib in human plasma. Biol. Pharm. Bull.<\/i>, 34, 1126\u20131128 (2011)."},{"key":"21","unstructured":"21) Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol.<\/i>, 51, 913\u2013921 (1997)."},{"key":"22","unstructured":"22) Sweet DH, Miller DS, Pritchard JB. Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J. Biol. Chem.<\/i>, 276, 41611\u201341619 (2001)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V. Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am. J. Physiol. Renal Physiol.<\/i>, 279, F449\u2013F458 (2000).","DOI":"10.1152\/ajprenal.2000.279.3.F449"},{"key":"24","unstructured":"24) Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation\/carnitine transporter. J. Pharmacol. Exp. Ther.<\/i>, 290, 1482\u20131492 (1999)."},{"key":"25","unstructured":"25) Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J. Pharmacol. Exp. Ther.<\/i>, 291, 778\u2013784 (1999)."},{"key":"26","unstructured":"26) Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther.<\/i>, 81, 495\u2013502 (2007)."},{"key":"27","unstructured":"27) Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos.<\/i>, 33, 518\u2013523 (2005)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Prenen H, Guetens G, de Boeck G, Debiec-Rychter M, Manley P, Schoffski P, van Oosterom AT, de Bruijn E. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology<\/i>, 77, 11\u201316 (2006).","DOI":"10.1159\/000091943"},{"key":"29","unstructured":"29) Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res.<\/i>, 14, 3141\u20133148 (2008)."},{"key":"30","unstructured":"30) Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab. Dispos.<\/i>, 38, 1371\u20131380 (2010)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Eadie LN, Saunders VA, Hughes TP, White DL. Degree of kinase inhibition achieved in vitro<\/i> by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leuk. Lymphoma<\/i>, 54, 569\u2013578 (2013).","DOI":"10.3109\/10428194.2012.715345"},{"key":"32","unstructured":"32) Kosztyu P, Dolezel P, Mlejnek P. Can P-glycoprotein mediate resistance to nilotinib in human leukaemia cells? Pharmacol. Res.<\/i>, 67, 79\u201383 (2013)."},{"key":"33","unstructured":"33) Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y, Maekawa T. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk. Res.<\/i>, 32, 980\u2013983 (2008)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/37\/8\/37_b14-00254\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T06:03:14Z","timestamp":1615874594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/37\/8\/37_b14-00254\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b14-00254","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}